Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-assisted group therapy for PTSD in veterans
NCT05961527Phase 2Completed
- Sponsor
- Portland VA Research Foundation
- Start
- Oct 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Portland VA Research Foundation. Primary endpoint: Change in Clinician Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score at 3 months. Started Oct 2023; status: completed.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05961527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05961527.